COAG Hemab Therapeutics, Inc.
Price Chart
Executive Summary
Hemab Therapeutics priced its IPO at $18.00 per share, offering 16.75M shares for gross proceeds of ~$301.5M, with an underwriter option for an additional 2.5125M shares. The stock begins trading on Nasdaq May 1, 2026 under ticker COAG. This is a dilutive event for existing holders but provides capital to advance its clinical pipeline in blood coagulation disorders.
Key Financial Metrics
Actionable Insight
Monitor first-day trading volume and price action for signs of demand. The $301.5M raise provides a multi-year cash runway for pipeline development, but as a clinical-stage company with no approved products, near-term catalysts depend on clinical trial data readouts for sutacimig and HMB-002.
Key Facts
- IPO priced at $18.00 per share for 16,750,000 shares
- Gross proceeds of approximately $301.5 million before expenses
- Underwriters have a 30-day option to purchase up to 2,512,500 additional shares
- Trading begins on Nasdaq Global Select Market on May 1, 2026 under ticker COAG
- Goldman Sachs, Jefferies, and Evercore ISI are joint book-running managers
- Offering expected to close on or about May 4, 2026
- Company is a clinical-stage biotech focused on blood coagulation disorders
Financial Impact
Gross proceeds of ~$301.5M from IPO, representing significant capital infusion for a clinical-stage biotech
Risk Factors
- Dilution for existing shareholders from the 16.75M share offering
- Clinical-stage company with no approved products or revenue
- Potential for underwriters to exercise overallotment option, adding further dilution
- Market conditions may affect post-IPO trading performance
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285621 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 21, 2026
19d ago
|
Press Release
| $26.30 $28.50 | ▲ +8.37% | ▲ +6.52% | $25.55 (−2.85%) |
|
May 4, 2026
5w ago
|
8-K
| $25.00 $25.90 | ▲ +3.60% | ▲ +1.62% | $25.55 (+2.20%) |
|
Apr 30, 2026
5w ago
|
Press Release
| $34.00 $25.12 | ▼ −26.12% | ▼ −28.46% | $25.55 (−24.85%) |
|
Apr 30, 2026
5w ago
|
3
| $34.00 $25.12 | ▼ −26.12% | ▼ −28.46% | $25.55 (−24.85%) |
|
Apr 30, 2026
5w ago
|
3
| $34.00 $25.12 | ▼ −26.12% | ▼ −28.46% | $25.55 (−24.85%) |
|
Apr 30, 2026
5w ago
|
3
| $34.00 $25.12 | ▼ −26.12% | ▼ −28.46% | $25.55 (−24.85%) |
|
Apr 30, 2026
5w ago
|
3
| $34.00 $25.12 | ▼ −26.12% | ▼ −28.46% | $25.55 (−24.85%) |
|
Apr 30, 2026
5w ago
|
3
| $34.00 $25.12 | ▼ −26.12% | ▼ −28.46% | $25.55 (−24.85%) |
|
Apr 30, 2026
5w ago
|
3
| $34.00 $25.12 | ▼ −26.12% | ▼ −28.46% | $25.55 (−24.85%) |
|
Apr 30, 2026
5w ago
|
3
| $34.00 $25.12 | ▼ −26.12% | ▼ −28.46% | $25.55 (−24.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access